PA
AMAG

Parallel Advisors’s AMAG Pharmaceuticals AMAG Stock Holding History

Parallel Advisors’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-70
Closed -$1K – 2177
2017
Q3 		$1K Hold
70
– – ﹤0.01% 2050
2017
Q2 		$1K Hold
70
– – ﹤0.01% 2051
2017
Q1 		$1K Hold
70
– – ﹤0.01% 1951
2016
Q4 		$2K Buy
+70
New +$2.09K ﹤0.01% 1663

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Parallel Advisors's AMAG Position: Q4 2017 in Review

Parallel Advisors sold out of AMAG Pharmaceuticals (AMAG) in Q4 2017, closing a stake of 70 shares — an estimated $1K sold.

Parallel Advisors first reported a position in AMAG in Q4 2016 and held it in 4 quarters. The position peaked at $2K in Q4 2016. 170 funds tracked by Wall St. Rank hold AMAG as of Q4 2017.

  • Parallel Advisors reported no remaining AMAG Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Parallel Advisors sold 70 AMAG Pharmaceuticals shares in Q4 2017, an estimated $1K.
  • Parallel Advisors first reported a position in AMAG Pharmaceuticals in Q4 2016 and held it in 4 quarters.
  • Parallel Advisors's AMAG Pharmaceuticals position peaked at $2K in Q4 2016.
  • 170 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2017.

Based on Parallel Advisors's 13F filing for Q4 2017, filed 13 Feb 2018.